Loading company
Just reported
From Novavax's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$68.3M
-3.0% y/y
+20% q/q
Guided
—
No guide given
Actual
-$0.19
Guided
—
No guide given
Actual
-$31.3M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Novavax is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now ABuilt from Novavax, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Company outlook: revenue of $170M to $180M for Fiscal year 2026 — down 84.4% on a year earlier ($1.1B)
Grade F
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Novavax, Inc.’s grade history. The other 39 go back to November 2016.
